ADVANCE – effects of intensive glucose lowering in type 2 diabetes Review article
Article Sidebar
Published:
Mar 31, 2009
Keywords:
ADVANCE, type 2 diabetes, gliclazide MR, micro- and macroangiopathy
Main Article Content
Abstract
The article describes the results of the glycemic arm of ADVANCE. The aim of the study was to evaluate the effects of tight glicemic control (HbA1c ≤6,5%) involving gliclazide (modified release) and other drugs as required in type 2 diabetic patients on micro- and macrovascular events. Patients in the intensive-glucose control group had lower the glycated hemoglobin value (6,5%), a 10% relative reduction in the combined outcome of macro- and microvascular events, including 21% reduction in the incidence of nephropathy.
Article Details
How to Cite
Szelachowska, M. (2009). ADVANCE – effects of intensive glucose lowering in type 2 diabetes. Medycyna Faktow (J EBM), 2(1(2), 9-14. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2676
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Juutilainen A., Lehto S., Rönnemaa T. et al.: Type 2 diabetes as a „coronary heart disease equivalent”. Diabetes Care 2005, 28: 2901-2907.
2. Stratton I.M., Adler A.L., Neil H.A. et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
3. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group. NEJM 2008, 358: 2560-2572.
4. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę. PTD 2008. Diabetologia Praktyczna 2008; 9 (supl. A).
5. Gaede P., Vedel P., Larsen N. et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. NEJM 2003, 348: 383-393.
6. Gaede P., Lund-Andersen H., Parking H.H., Pedersen O.: Effect of multifactorial intervention on mortality in type 2 diabetes. NEJM 2008, 358: 580-501.
7. Effects of intensive glucose lowering in type 2 diabetes. The Action to Controll Cardiovascular Risk in Diabetes Study Group. NEJM 2008, 358: 2545-2559.
8. Abraira C., Duckworth W.C., Moritz T.: Glycemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity and Metabolism 2008; doi: 10.1111/j.
9. Ismail-Beigi F., Moghissi E.: Glycemia management and cardiovascular risk in type 2 diabetes: an evolving perspective. Endocrine Practice 2008, 14: 639-643.
10. Holman R.R., Paul S.K., Betel A. et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. NEJM 2008: 359.
2. Stratton I.M., Adler A.L., Neil H.A. et al.: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
3. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group. NEJM 2008, 358: 2560-2572.
4. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę. PTD 2008. Diabetologia Praktyczna 2008; 9 (supl. A).
5. Gaede P., Vedel P., Larsen N. et al.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. NEJM 2003, 348: 383-393.
6. Gaede P., Lund-Andersen H., Parking H.H., Pedersen O.: Effect of multifactorial intervention on mortality in type 2 diabetes. NEJM 2008, 358: 580-501.
7. Effects of intensive glucose lowering in type 2 diabetes. The Action to Controll Cardiovascular Risk in Diabetes Study Group. NEJM 2008, 358: 2545-2559.
8. Abraira C., Duckworth W.C., Moritz T.: Glycemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes, Obesity and Metabolism 2008; doi: 10.1111/j.
9. Ismail-Beigi F., Moghissi E.: Glycemia management and cardiovascular risk in type 2 diabetes: an evolving perspective. Endocrine Practice 2008, 14: 639-643.
10. Holman R.R., Paul S.K., Betel A. et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. NEJM 2008: 359.